Maintenance erlotinib in advanced nonsmall cell lung cancer: Cost-effectiveness in EGFR wild-type across Europe

ClinicoEconomics and Outcomes Research

Volumn 4, Issue 1, 2012, Pages 269-275

  Walleser, Silke ^a   Ray, Joshua ^b   Bischoff, Helge ^c   Vergnenègre, Alain ^d   Rosery, Hubertus ^e   Chouaid, Christos ^f   Heigener, David ^g   Carpeño, Javier de Castro ^h   Tiseo, Marcello ⁱ   Walzer, Stefan ^b  

^a Health Economic Consultancy ^*  (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c Thoracic Hospital of Heidelberg   (Germany)

^d LIMOGES UNIVERSITY HOSPITAL   (France)

^e Assessment in Medicine GmbH   (Germany)

^f HÔPITAL SAINT ANTOINE   (France)

^g KRANKENHAUS GROSSHANSDORF   (Germany)

^h HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁱ UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

Cost benefit analysis; Epidermal growth factor receptor; Erlotinib; Europe; Nonsmall cell lung cancer; Wild type

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERLOTINIB;

ADVANCED CANCER; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MAINTENANCE CHEMOTHERAPY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; WILD TYPE;

EID: 84866545825     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. NCCN Guidelines - Clinical Practice Guidelines in Oncology. Non-small cell lung cancer. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed May 16, 2012.
3. D'Addario G, Fruh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(5):116-119.
4. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol. 2000;18(2):106-115.
5. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol. 2007;2(8):706-714.
6. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 2009;28(1):24-31.
7. Ramalingam S, Belani C. Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist. 2008;13(1):5-13.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
9. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a Phase III trial. Lung Cancer. 2006;52(2):155-163.
10. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol. 2009;27(4):591-598.
11. European Medicines Agency. Tarceva (erlotinib) - EU label and approval. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000618/WC500033994.pdf. Accessed May 16, 2012.
12. US Food and Drug Administration. Tarceva (erlotinib) - FDA label and approval. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf. Accessed May 16, 2012.
13. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase 3 study. Lancet Oncol. 2010;11(6):521-529.
14. Vergnenègre A, Ray J, Chouaid C, et al. Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer. Clinicoecon Outcomes Res. 2012;4(1):31-37.
15. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
16. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123-132.
17. Hanna N, Shepherd FA, Fossella FV, et al. Randomized Phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9):1589-1597.
18. European Medicines Agency. Alimta (pemetrexed) - EU label and approval. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000564/WC500025611.pdf. Accessed May 16, 2012.
19. Casciano R, Bischoff H, Nuijten M, Malangone E, Ray J. Maintenance erlotinib versus pemetrexed for the treatment of non-small cell lung cancer: indirect comparison applying real-life outcomes. Proceedings of the International Society for Pharmacoeconomics and Outcomes Research 13th Annual European Congress, November 6-9, 2010; Prague, Czech Republic.
20. Nuijten MJ, de Castro CJ, Chouaid C, et al. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 2012;76(3):465-471.
21. Ontario Health Technology Advisory Committee. Epidermal growth factor receptor (EGFR) mutation testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer. Presented at the Ontario Health Technology Advisory committee in August, 2010. Available at: http://www.health.gov.on.ca/english/providers/program/ohtac/tech/recommend/rec_EGFR_20101209.pdf. Accessed May 16, 2012.
22. Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst. 2010;102(5):298-306.